25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Patent number: 10849957Abstract: Making an initial evaluation of patient's joint pain when undergoing motions associated stress to the joint such as going up and down stairs, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion is disclosed.Type: GrantFiled: June 12, 2018Date of Patent: December 1, 2020Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 10842879Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 16, 2016Date of Patent: November 24, 2020Assignee: UNIVERSITY OF MIYAZAKIInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 10799559Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.Type: GrantFiled: April 24, 2017Date of Patent: October 13, 2020Assignees: Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development LimitedInventors: Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
-
Patent number: 10738094Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 30, 2016Date of Patent: August 11, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10697001Abstract: Provided herein are devices and methods for the capture or isolation of a biomarker from a biological sample. In several embodiments, the device comprises a loading region, a filter material, and a receiving region. In particular, in several embodiments, biological fluid is passed from the loading region through the filter material and into the receiving region, thereby resulting in capture or isolation of a biomarker.Type: GrantFiled: March 10, 2017Date of Patent: June 30, 2020Assignees: HITACHI CHEMICAL CO., LTD., HITACHI CHEMICAL CO. AMERICA, LTD.Inventors: Masato Mitsuhashi, Taku Murakami
-
Patent number: 10696946Abstract: This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases.Type: GrantFiled: November 3, 2017Date of Patent: June 30, 2020Assignee: The Board of Trustees of the University of IllinoisInventor: Bellur Prabhakar
-
Patent number: 10654915Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.Type: GrantFiled: December 5, 2012Date of Patent: May 19, 2020Assignee: TRELLIS BIOSCIENCE, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
-
Patent number: 10617736Abstract: This invention relates to a method of increasing energy available to skeletal muscle cells comprising administering to the cells an effective amount of Tenurin C-terminal Associated Peptide (TCAP). The invention provides the use of TCAP to enhance muscle performance or recovery after injury as well as to prevent and/or treat a number of conditions including insulin resistance, type II diabetes, hypoxia and glycogen storage diseases.Type: GrantFiled: July 21, 2015Date of Patent: April 14, 2020Inventors: Yani Chen, David Lovejoy
-
Patent number: 10596265Abstract: A nanogel comprising a self-organizing peptide, a chitosan and polyethylene glycol is described.Type: GrantFiled: August 24, 2015Date of Patent: March 24, 2020Assignees: 3-D Matrix, Ltd., Tokyo University of Science FoundationInventors: Hidenori Otsuka, Daisuke Matsukuma
-
Patent number: 10548945Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.Type: GrantFiled: April 22, 2014Date of Patent: February 4, 2020Assignee: AFFILOGICInventor: Olivier Kitten
-
Patent number: 10544220Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.Type: GrantFiled: January 8, 2016Date of Patent: January 28, 2020Assignee: GENMAB A/SInventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
-
Patent number: 10532040Abstract: The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and/or skin cancer in a mammal.Type: GrantFiled: November 19, 2012Date of Patent: January 14, 2020Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Ann M. Bode, Young-Yeon Cho, Zigang Dong, Dong Joon Kim
-
Patent number: 10533039Abstract: The present invention provides peptides comprising a sequence of X?6X?5X?4X?3X?2X?1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26 YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X?6, X?5, X?4, X?3, X?2, X?1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.Type: GrantFiled: May 21, 2015Date of Patent: January 14, 2020Assignee: President and Fellows of Harvard CollegeInventors: Gregory L. Verdine, John Hanney McGee
-
Patent number: 10533044Abstract: Provided herein are integrin antagonists and methods of using the same. For example, one or more of the compounds or polypeptides provided herein can be used in the treatment of disorders such as heart attacks, stroke, and cancer metastasis. Also provided herein is a crystal comprising ?v?3 ectodomain complexed with inhibitor knottin 2.5 F. Further provided herein is a crystal comprising ?V?3 ectodomain complexed with inhibitor hFN10. In another aspect, the invention features a method that includes using a three-dimensional model of a complex that includes an integrin ectodomain.Type: GrantFiled: January 6, 2015Date of Patent: January 14, 2020Assignee: The General Hospital CorporationInventor: M. Amin Arnaout
-
Patent number: 10501498Abstract: Provided is a new conotoxin peptide ?-CPTx-bt101. The conotoxin peptide ?-CPTx-bt101 has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1, or has derivative polypeptide that has an amino acid sequence indicated by SEQ ID NO:1 and that is formed after substitution, addition or deletion of one or more amino acids are performed and has original functions. Also provided is polynucleotide for coding the peptide, comprising a constructed body of the polynucleotide, an expression carrier and transformed cells. A peptide preparation method and uses in the treatment of diseases related to a calcium ion channel.Type: GrantFiled: December 26, 2014Date of Patent: December 10, 2019Assignee: BGI SHENZHENInventors: Jie Liu, Zhilong Lin, Bo Wen, Ting Tong, Fen Mo, Chao Peng, Qiong Shi
-
Patent number: 10478524Abstract: This invention relates to a lamellae tissue layer, comprising a grooved silk fibroin substrate comprising tissue-specific cells. The silk fibroin substrates provides an excellent means of controlling and culturing cell and extracellular matrix development. A multitude of lamellae tissue layers can be used to create a tissue-engineered organ, such as a tissue-engineered cornea. The tissue-engineered organ is non-immunogenic and biocompatible.Type: GrantFiled: May 19, 2017Date of Patent: November 19, 2019Assignee: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Fiorenzo G. Omenetto, Jeffrey K. Marchant, Noorjahan Panjwani, Brian Lawrence
-
Patent number: 10470461Abstract: Disclosed are hypersensitive-response eliciting peptides that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.Type: GrantFiled: February 5, 2016Date of Patent: November 12, 2019Assignee: Plant Health Care, Inc.Inventors: Zhongmin Wei, Gregory A. Zornetzer, Stephen Bornick
-
Patent number: 10472389Abstract: The present invention provides methods for increasing purity of an Fc-containing protein by removing protein aggregates during the Protein A chromatography step used during the purification of the Fc-containing protein.Type: GrantFiled: March 7, 2014Date of Patent: November 12, 2019Assignee: EMD Millipore CorporationInventors: Nanying Bian, Melissa Holstein
-
Patent number: 10471163Abstract: Provided herein are methods for determining the presence or absence of active thrombus formation using a linear polypeptide that binds fibrin upon cyclization. Also provided are compounds comprising linear polypeptide probes that are cyclized in the presence of protein disulfide isomerase.Type: GrantFiled: September 12, 2014Date of Patent: November 12, 2019Assignee: The General Hospital CorporationInventors: Galen Loving, Peter D. Caravan
-
Patent number: 10472401Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 30, 2016Date of Patent: November 12, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10464978Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 30, 2016Date of Patent: November 5, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10358469Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. In particular, the present invention relates to a polypeptide comprising or consisting of i) an amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, ii) an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1, or iii) an amino acid sequence which is a retro-inverso of the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1 or, iv) an amino acid sequence which is retro-inverso of the amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the phenylalanine residue at position 380 to the leucine residue at position 384 in SEQ ID NO: 1.Type: GrantFiled: February 17, 2015Date of Patent: July 23, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP)Inventors: Jean-Luc Poyet, Heriberto Bruzzoni-Giovanelli, Léonard Jagot-Lacoussiere
-
Patent number: 10323070Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: GrantFiled: May 31, 2017Date of Patent: June 18, 2019Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventor: Steven J. Norris
-
Patent number: 10308693Abstract: The invention provides a peptide comprising: a core amino acid sequence, which is identical or similar to the amino acid sequence of a member of the Cecropin family. The invention further provides a nucleic acid sequence encoding the peptide and a vector comprising said nucleic acid. The invention further provides a pharmaceutical composition comprising said peptide or said nucleic acid. The invention further provides methods of treating an infection, overcoming inherent or acquired resistance of a microorganism to an antibiotic agent or disinfecting a wound, the methods comprises administering the peptide to a subject in need thereof.Type: GrantFiled: February 17, 2016Date of Patent: June 4, 2019Assignee: OMNIX MEDICAL LTD.Inventors: Niv Bachnoff, Moshe Cohen-Kutner
-
Patent number: 10273290Abstract: The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating the viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.Type: GrantFiled: September 21, 2017Date of Patent: April 30, 2019Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Loren D. Walensky, Gregory Bird
-
Patent number: 10261082Abstract: The invention provides for a method for the detection of FeLV infection in a patient, wherein a sample obtained from the patient is contacted in-vitro with a recombinant transmembrane p15E protein in a p15 (E) antibody binding step.Type: GrantFiled: October 15, 2016Date of Patent: April 16, 2019Assignee: UNIVERSITAT ZURICHInventors: Hans Lutz, Eva Bonzli, Regina Hofmann-Lehmann
-
Patent number: 10259850Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.Type: GrantFiled: February 3, 2016Date of Patent: April 16, 2019Assignee: MEDPACTO INC.Inventors: Il Ho Ha, Seok Ho Yoo, Hye Nan Kim, Yeung Chul Kim, Ju Ry Lim
-
Patent number: 10238757Abstract: A molecular probe for use in detection of cancer cells expressing an Ig superfamily cell adhesion molecule that binds in a homophilic fashion in a subject includes a targeting agent that specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of the Ig superfamily cell adhesion molecule.Type: GrantFiled: February 24, 2014Date of Patent: March 26, 2019Assignee: CASE WESTERN RESERVE UNIVERSITYInventor: Susann Brady-Kalnay
-
Patent number: 10221216Abstract: Described herein are recognition modules that bind specifically to a template nucleic acid and which ligate together in a reducing environment to produce a gamma peptide nucleic acid (?PNA) oligomer. Also provided are methods of synthesizing a ?PNA oligomer on a template using the recognition modules.Type: GrantFiled: April 11, 2014Date of Patent: March 5, 2019Assignee: Carnegie Mellon UniversityInventors: Danith H. Ly, Raman Bahal, Arunava Manna, Dinesh Chandra Bhunia, Rapireddy Srinivas, Yidan Cong
-
Patent number: 10213486Abstract: A formulation of a diluted amino acid fragment is prepared by mixing an amino acid fragment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid fragment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.Type: GrantFiled: March 27, 2017Date of Patent: February 26, 2019Assignee: Deseret Biologicals, Inc.Inventors: Jacob L. Carter, Edwin Douglas Lephart
-
Patent number: 10183986Abstract: A collagen scaffold domain, including a collagenous or collagen-like domain, which directs self-trimerization is provided. The collagen scaffold domain can be fused to one or more heterologous domains, such as an antibody domain. Methods for generating and using the scaffold domains and fusion proteins are also provided.Type: GrantFiled: November 30, 2007Date of Patent: January 22, 2019Assignee: Industrial Technology Research InstituteInventors: Min-Yuan Chou, Chia-Yu Fan, Chuan-Chuan Huang, Hsiu-Chuan Li
-
Patent number: 10155804Abstract: To provide a differentiation-inducing composition and a method for producing the differentiation-inducing composition, the present disclosure describes use of a degradation product containing at least a portion of the triple helical domain of collagen or atelocollagen.Type: GrantFiled: April 30, 2015Date of Patent: December 18, 2018Assignee: Kinki UniversityInventors: Koichi Morimoto, Saori Kunii, Ei Yamamoto, Hiroyuki Ito, Yoshinori Kuboki
-
Patent number: 10130692Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.Type: GrantFiled: January 26, 2012Date of Patent: November 20, 2018Assignee: Qu Biologics Inc.Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Patent number: 10010614Abstract: The invention relates to derivatives of GLP-1 like peptides which are C-terminally extended analogs of native GLP-1. The derivatives comprise two side chains, one at a position corresponding to position 42, and one at a position corresponding to position 18, 23, 27, 31, 36, or 38, wherein both positions are when compared to GLP-1(7-37). The side chains comprise a C19, C20, or C22 diacid protracting moiety and optionally a linker. The invention also relates to intermediate products in the form of novel GLP-1 analogs incorporated in the derivatives of the invention, as well as pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.Type: GrantFiled: September 28, 2016Date of Patent: July 3, 2018Assignee: Novo Nordisk A/SInventors: Steffen Reedtz-Runge, Jacob Kofoed
-
Patent number: 10005822Abstract: A system, including methods and compositions, for treatment of ischemia.Type: GrantFiled: May 27, 2016Date of Patent: June 26, 2018Assignee: MOREHOUSE SCHOOL OF MEDICINEInventors: Roger P. Simon, Zhi-Gang Xiong
-
Patent number: 9999694Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.Type: GrantFiled: March 17, 2014Date of Patent: June 19, 2018Assignees: Sloan-Kettering Institute for Cancer Research, Cornell UniversityInventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
-
Patent number: 9975932Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.Type: GrantFiled: December 17, 2010Date of Patent: May 22, 2018Assignee: Merck Patent GmbHInventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
-
Patent number: 9969969Abstract: A process for producing plasmid DNA E. coli cells comprises a pre-culture and fed-batch process. The culture media of the batch phase and the culture medium added during the feeding phase are chemically defined. The culture medium of the feeding phase contains a growth-limiting substrate and is added, for at least a fraction of the feeding phase, at a feeding rate that follows a pre-defined exponential function, thereby controlling the specific growth rate at a pre-defined value. The process results in high yield and homogeneity of plasmid DNA.Type: GrantFiled: February 19, 2009Date of Patent: May 15, 2018Assignee: BOEHRINGER INGELHEIM RCV GMBH & CO KGInventors: Hans Huber, Gerhard Weigl, Wolfgang Buchinger
-
Patent number: 9920356Abstract: An object of the invention is to provide a nucleic acid detection method which takes advantage of the high specificity of hybridization techniques, reduces the time length and the number of steps required for detection of PCR products, and allows for easy and highly accurate detection by visual observation without the need of special equipment; and a nucleic acid detection device or kit. The invention provides a method for detecting a target nucleic acid in a sample, which includes performing amplification of the target nucleic acid sequence to synthesize an amplification product having a partially double-stranded structure where a single-stranded region is added to each end of the target sequence, and hybridizing a nucleic acid sequence bound to a development medium and a nucleic acid sequence labeled with a labeling compound with the single-stranded regions of the amplification product to form a sandwich hybridization complex; and a detection device thereof.Type: GrantFiled: November 24, 2011Date of Patent: March 20, 2018Assignee: KANEKA CORPORATIONInventors: Koji Takahashi, Shigehiko Miyamoto, Takaaki Jikihara, Jun Tomono
-
Patent number: 9913878Abstract: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (?5?1) or vitronectin (?v?3 and ?v?5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.Type: GrantFiled: January 26, 2016Date of Patent: March 13, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Richard H. Kimura, Aron M. Levin
-
Patent number: 9879327Abstract: Methods and compositions for detecting, identifying, and quantifying Brassica A genomic DNA are described. The methods are specific to the Brassica A genome and do not cross-react with other Brassica species, crops or weedy relatives that could contribute to contamination of a canola field.Type: GrantFiled: April 14, 2016Date of Patent: January 30, 2018Assignee: E. I. DU PONT DE NEMOURS AND COMPANYInventors: Matthew Curtis Harmon, Nancy L Henderson, Cathy Xiaoyan Zhong
-
Patent number: 9879071Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.Type: GrantFiled: September 5, 2012Date of Patent: January 30, 2018Assignee: Prothena Biosciences LimitedInventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
-
Patent number: 9872825Abstract: An object of the present invention to discover a short peptide having an anti-aging effect and to provide a novel anti-aging agent comprising the peptide as an active ingredient. The inventors have discovered that a peptide consisting of an amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 1) or a partial sequence thereof and having one or more effects selected from the group consisting of promoting fibroblast growth, promoting hyaluronic acid production and contracting a collagen gel, or a derivative or salt of the peptide is useful as an active ingredient of an anti-aging agent.Type: GrantFiled: March 27, 2014Date of Patent: January 23, 2018Assignee: Osaka UniversityInventors: Hironori Nakagami, Ryuichi Morishita, Hideki Tomioka, Akiko Tenma
-
Patent number: 9872919Abstract: The present invention provides a compound having the structure: wherein X is a therapeutic agent containing at least one amine nitrogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon ?; Z is CH3 or CF3; R1 is —H, —NR2R3, —NH—C(?O)—R4, —NH—C(?O)—OR4, —CH2—C(?O)—NR5R6, —OR7, —CO2R7, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, or heteroaryl, wherein R2, R3, R4, R5, R6 and R7 are each, independently, —H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6; or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.Type: GrantFiled: September 18, 2013Date of Patent: January 23, 2018Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Nobuhide Ueki, Michael J. Hayman
-
Patent number: 9862837Abstract: The invention provided herein presents a novel family of antifouling agents based on hydroxylated and fluorinated compounds.Type: GrantFiled: June 27, 2016Date of Patent: January 9, 2018Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTDInventor: Meital Reches
-
Patent number: 9855312Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.Type: GrantFiled: December 23, 2013Date of Patent: January 2, 2018Assignees: UNIVERSITY OF MIAMI, THE UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSInventors: Andrew V. Schally, Joshua M. Hare, Norman L. Block, Samirah A. Gomes, Rosemeire M. Kanashiro-Takeuchi
-
Patent number: 9783610Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.Type: GrantFiled: March 15, 2013Date of Patent: October 10, 2017Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: George Coukos, Chunsheng Li
-
Patent number: 9758548Abstract: A method of treating a bacterial infection in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide being between 3 and 5 amino acids, wherein at least one amino acid of the 3 and 5 amino acids is selected from the group consisting of tryptophan, cysteine, proline and methionine.Type: GrantFiled: May 10, 2012Date of Patent: September 12, 2017Assignee: Technion Research & Development Foundation LimitedInventors: Noam Adir, Sharon Navon, Tali Swartzmann
-
Patent number: 9717775Abstract: The present invention relates to the use of compounds that block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the ?9?10 subtype of the nAChR.Type: GrantFiled: July 17, 2007Date of Patent: August 1, 2017Assignee: University of Utah Research FoundationInventors: J. Michael McIntosh, Baldomero M. Olivera, Michael A. Ellison, Michelle Vincler
-
Patent number: 9700598Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.Type: GrantFiled: April 8, 2015Date of Patent: July 11, 2017Assignee: PHASEBIO PHARMACEUTICALS, INC.Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner